Molecular Characterization of a Novel Geranylgeranyl Pyrophosphate Synthase from Plasmodium Parasites

We present here a study of a eukaryotic trans-prenylsynthase from the malaria pathogen Plasmodium vivax. Based on the results of biochemical assays and contrary to previous indications, this enzyme catalyzes the production of geranylgeranyl pyrophosphate (GGPP) rather than farnesyl pyrophosphate (FPP). Structural analysis shows that the product length is constrained by a hydrophobic cavity formed primarily by a set of residues from the same subunit as the product as well as at least one other from the dimeric partner. Furthermore, Plasmodium GGPP synthase (GGPPS) can bind nitrogen-containing bisphosphonates (N-BPs) strongly with the energetically favorable cooperation of three Mg2+, resulting in inhibition by this class of compounds at IC50 concentrations below 100 nm. In contrast, human and yeast GGPPSs do not accommodate a third magnesium atom in the same manner, resulting in their insusceptibility to N-BPs. This differentiation is in part attributable to a deviation in a conserved motif known as the second aspartate-rich motif: whereas the aspartates at the start and end of the five-residue motif in FFPP synthases and P. vivax GGPPSs both participate in the coordination of the third Mg2+, an asparagine is featured as the last residue in human and yeast GGPPSs, resulting in a different manner of interaction with nitrogen-containing ligands.

[1]  Eric Oldfield,et al.  Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: Implications for drug design , 2005, Proteins.

[2]  H. Rilling,et al.  Crystallization and partial characterization of prenyltransferase from avian liver. , 1975, Biochemistry.

[3]  Li Li,et al.  PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data , 2003, Nucleic Acids Res..

[4]  E. Oldfield,et al.  Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. , 2001, Journal of medicinal chemistry.

[5]  K. Kavanagh,et al.  Targeting a uniquely nonspecific prenyl synthase with bisphosphonates to combat cryptosporidiosis. , 2008, Chemistry & biology.

[6]  E. Oldfield,et al.  Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. , 2002, Journal of medicinal chemistry.

[7]  D. Chakrabarti,et al.  Protein Farnesyltransferase and Protein Prenylation inPlasmodium falciparum * , 2002, The Journal of Biological Chemistry.

[8]  Udo Oppermann,et al.  Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. , 2008, Journal of medicinal chemistry.

[9]  M. Clastre,et al.  The methylerythritol phosphate pathway for isoprenoid biosynthesis in coccidia: presence and sensitivity to fosmidomycin. , 2007, Experimental parasitology.

[10]  Wolfgang Jahnke,et al.  Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs , 2006, ChemMedChem.

[11]  Po-Huang Liang,et al.  Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. , 2008, Journal of medicinal chemistry.

[12]  Alexey Bochkarev,et al.  Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. , 2007, Molecular and biochemical parasitology.

[13]  S. Knapp,et al.  The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Oldfield,et al.  (31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth. , 2001, Biochemical and biophysical research communications.

[15]  E. Oldfield,et al.  Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data. , 2008, Journal of medicinal chemistry.

[16]  E. Oldfield,et al.  Lipophilic Bisphosphonates Are Potent Inhibitors of Plasmodium Liver-Stage Growth , 2010, Antimicrobial Agents and Chemotherapy.

[17]  E. Oldfield,et al.  Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. , 2004, Journal of medicinal chemistry.

[18]  P. Kroon,et al.  Isoprenyl diphosphate synthases: Protein sequence comparisons, a phylogenetic tree, and predictions of secondary structure , 1994, Protein science : a publication of the Protein Society.

[19]  J. Sacchettini,et al.  Crystal structure of recombinant farnesyl diphosphate synthase at 2.6-A resolution. , 1994, Biochemistry.

[20]  J C Sacchettini,et al.  Regulation of product chain length by isoprenyl diphosphate synthases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Gurmukh Sahota,et al.  Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. , 2005, Journal of medicinal chemistry.

[22]  E. Oldfield,et al.  Bisphosphonates Are Potent Inhibitors of Trypanosoma cruzi Farnesyl Pyrophosphate Synthase* , 2001, The Journal of Biological Chemistry.

[23]  C. Poulter,et al.  Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. , 2001, The Journal of pharmacology and experimental therapeutics.

[24]  E. Oldfield,et al.  The Farnesyl-diphosphate/Geranylgeranyl-diphosphate Synthase of Toxoplasma gondii Is a Bifunctional Enzyme and a Molecular Target of Bisphosphonates* , 2007, Journal of Biological Chemistry.

[25]  E. Oldfield,et al.  Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases , 2007, Proceedings of the National Academy of Sciences.

[26]  A. H. Wang,et al.  Crystal Structure of Type-III Geranylgeranyl Pyrophosphate Synthase from Saccharomyces cerevisiae and the Mechanism of Product Chain Length Determination* , 2006, Journal of Biological Chemistry.

[27]  Udo Oppermann,et al.  The Crystal Structure of Human Geranylgeranyl Pyrophosphate Synthase Reveals a Novel Hexameric Arrangement and Inhibitory Product Binding* , 2006, Journal of Biological Chemistry.

[28]  D. Chakrabarti,et al.  Protein prenyl transferase activities of Plasmodium falciparum. , 1998, Molecular and biochemical parasitology.

[29]  T. Nishino,et al.  A Role of the Amino Acid Residue Located on the Fifth Position before the First Aspartate-rich Motif of Farnesyl Diphosphate Synthase on Determination of the Final Product* , 1996, The Journal of Biological Chemistry.